Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.

Journal of clinical microbiology - 1 Nov 2002

Rodés Berta, Poveda Eva, Soriano Vincent

Abstract excerpt

A bacteriophage lambda-based method was used to investigate the development of resistance to protease inhibitors (PI) in one subject infected with human immunodeficiency virus (HIV) type 1 group O who underwent multiple treatment regimens over a period of 4 years. A reduction in the susceptibility to indinavir of 6-fold and a reduction in the susceptibility to saquinavir of 24-fold were recognized after long...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteriophage lambda
Share to Drug Resistance, Viral
Share to HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Indinavir

Share to Microbial Sensitivity Tests

Share to Saquinavir

Source

Open in PubMed Open full text

Identifiers

PMID: 12409418
DOI: 10.1128/JCM.40.11.4313-4316.2002
PMCID: PMC139640

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.PMID 12409418Read ↗

Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.Semantic proximity Read ↗

Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analysesSemantic proximity Read ↗

Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M.Semantic proximity Read ↗

Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor.Semantic proximity Read ↗

Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.Semantic proximity Read ↗

Rapid genetic selection of inhibitor-resistant protease mutants: clinically relevant and novel mutants of the HIV protease.Semantic proximity Read ↗

Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors.Semantic proximity Read ↗

Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.Semantic proximity Read ↗

HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.Semantic proximity Read ↗

Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.Semantic proximity Read ↗

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals.Semantic proximity Read ↗

In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.